Alliancebernstein L.P. Savara Inc Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Savara Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 100,770 shares of SVRA stock, worth $300,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

100,770

Previous 100,770 -0.0%

Holding current value

$300,294

Previous $406,000 5.17%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $244,012 - $356,017	66,670 Added 195.51%	100,770 $406,000
Q1 2024 May 14, 2024	BUY	$4.19 - $5.59 $48,562 - $64,788	11,590 Added 51.49%	34,100 $169,000
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $11,161 - $17,199	3,510 Added 18.47%	22,510 $105,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $20,968 - $27,392	7,060 Added 59.13%	19,000 $71,000
Q2 2023 Aug 15, 2023	BUY	$1.69 - $3.24 $20,178 - $38,685	11,940 New	11,940 $38,000
Q2 2021 Jul 30, 2021	SELL	$1.51 - $2.29 $67,799 - $102,821	-44,900 Closed	0 $0
Q4 2020 Feb 08, 2021	SELL	$1.0 - $1.47 $1,600 - $2,352	-1,600 Reduced 3.44%	44,900 $52,000
Q3 2020 Nov 12, 2020	SELL	$1.09 - $2.21 $11,990 - $24,310	-11,000 Reduced 19.13%	46,500 $51,000
Q2 2020 Aug 13, 2020	BUY	$1.8 - $3.05 $12,420 - $21,045	6,900 Added 13.64%	57,500 $143,000
Q1 2020 May 14, 2020	BUY	$1.91 - $4.08 $7,831 - $16,728	4,100 Added 8.82%	50,600 $107,000
Q2 2019 Aug 14, 2019	BUY	$2.37 - $11.7 $60,909 - $300,690	25,700 Added 123.56%	46,500 $110,000
Q1 2019 May 14, 2019	BUY	$6.71 - $8.6 $49,654 - $63,640	7,400 Added 55.22%	20,800 $153,000
Q4 2018 Feb 13, 2019	BUY	$6.27 - $10.92 $17,556 - $30,576	2,800 Added 26.42%	13,400 $101,000
Q3 2018 Nov 08, 2018	BUY	$10.49 - $12.87 $111,194 - $136,422	10,600 New	10,600 $118,000

Others Institutions Holding SVRA

# of Institutions

128

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $340M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Savara Inc Transaction History